A Dual-Targeted Reset: CAR-T Therapy Reboots the Immune System in Lupus
A new study in Arthritis & Rheumatology investigates the profound immune reconstitution following BCMA-CD19 dual-targeting CAR-T cell therapy in patients with systemic lupus erythematosus (SLE). Using single-cell RNA sequencing and immune repertoire analysis on peripheral blood mononuclear cells, researchers compared outcomes in five SLE patients receiving the dual-targeting therapy to public data from patients treated with single-targeting CD19 CAR-T. The dual-targeting approach induced a deeper and more comprehensive depletion of pathogenic B-lineage populations, including plasma-lineage cells that often persist after CD19-only therapy. This was accompanied by a significant shift in the B cell receptor repertoire toward a healthier, IGHM-dominant, naïve-biased profile and a marked suppression of disease-associated interferon signaling pathways. Clinical improvement was robust, with the mean SLE Disease Activity Index score decreasing significantly, paralleling these molecular changes.
Study Significance: For hematologists and specialists in cellular therapies, this research provides critical mechanistic insights into how advanced CAR-T engineering can achieve a more complete humoral reset in autoimmune disease. The findings suggest that targeting both BCMA and CD19 may offer a superior strategy for depleting the autoreactive B-cell and plasma-cell compartments that drive conditions like SLE, moving beyond the limitations of single-antigen approaches. This exploratory evidence directly informs the strategic development of next-generation immunotherapies for a range of antibody-mediated disorders, potentially reshaping clinical trial design and therapeutic targeting in hematology and autoimmunity.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
